JP2020176155A5 - - Google Patents

Download PDF

Info

Publication number
JP2020176155A5
JP2020176155A5 JP2020134733A JP2020134733A JP2020176155A5 JP 2020176155 A5 JP2020176155 A5 JP 2020176155A5 JP 2020134733 A JP2020134733 A JP 2020134733A JP 2020134733 A JP2020134733 A JP 2020134733A JP 2020176155 A5 JP2020176155 A5 JP 2020176155A5
Authority
JP
Japan
Prior art keywords
composition
patient
treatment
egfr
compared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020134733A
Other languages
English (en)
Japanese (ja)
Other versions
JP7113871B2 (ja
JP2020176155A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020176155A publication Critical patent/JP2020176155A/ja
Priority to JP2021053174A priority Critical patent/JP2021095421A/ja
Publication of JP2020176155A5 publication Critical patent/JP2020176155A5/ja
Application granted granted Critical
Publication of JP7113871B2 publication Critical patent/JP7113871B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020134733A 2012-10-08 2020-08-07 高血圧症及び高カリウム血症を治療するためのカリウム結合剤 Active JP7113871B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021053174A JP2021095421A (ja) 2012-10-08 2021-03-26 高血圧症及び高カリウム血症を治療するためのカリウム結合剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261711184P 2012-10-08 2012-10-08
US61/711,184 2012-10-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017255122A Division JP6817185B2 (ja) 2012-10-08 2017-12-29 高血圧症及び高カリウム血症を治療するためのカリウム結合剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021053174A Division JP2021095421A (ja) 2012-10-08 2021-03-26 高血圧症及び高カリウム血症を治療するためのカリウム結合剤

Publications (3)

Publication Number Publication Date
JP2020176155A JP2020176155A (ja) 2020-10-29
JP2020176155A5 true JP2020176155A5 (cg-RX-API-DMAC7.html) 2021-05-06
JP7113871B2 JP7113871B2 (ja) 2022-08-05

Family

ID=49385427

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015535893A Active JP6475624B2 (ja) 2012-10-08 2013-10-08 高血圧症及び高カリウム血症を治療するためのカリウム結合剤
JP2017255122A Active JP6817185B2 (ja) 2012-10-08 2017-12-29 高血圧症及び高カリウム血症を治療するためのカリウム結合剤
JP2020134733A Active JP7113871B2 (ja) 2012-10-08 2020-08-07 高血圧症及び高カリウム血症を治療するためのカリウム結合剤
JP2021053174A Withdrawn JP2021095421A (ja) 2012-10-08 2021-03-26 高血圧症及び高カリウム血症を治療するためのカリウム結合剤

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2015535893A Active JP6475624B2 (ja) 2012-10-08 2013-10-08 高血圧症及び高カリウム血症を治療するためのカリウム結合剤
JP2017255122A Active JP6817185B2 (ja) 2012-10-08 2017-12-29 高血圧症及び高カリウム血症を治療するためのカリウム結合剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021053174A Withdrawn JP2021095421A (ja) 2012-10-08 2021-03-26 高血圧症及び高カリウム血症を治療するためのカリウム結合剤

Country Status (11)

Country Link
US (6) US10813946B2 (cg-RX-API-DMAC7.html)
EP (2) EP2916851B1 (cg-RX-API-DMAC7.html)
JP (4) JP6475624B2 (cg-RX-API-DMAC7.html)
KR (2) KR20210005314A (cg-RX-API-DMAC7.html)
CN (2) CN104822383A (cg-RX-API-DMAC7.html)
AU (3) AU2013329451B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015007749A2 (cg-RX-API-DMAC7.html)
CA (1) CA2886788C (cg-RX-API-DMAC7.html)
ES (1) ES3059226T3 (cg-RX-API-DMAC7.html)
HK (1) HK1210705A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014058905A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022380A2 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
ES3059226T3 (en) 2012-10-08 2026-03-19 Vifor Int Ltd Potassium-binding agents for treating hypertension and hyperkalemia
KR102633597B1 (ko) 2013-06-05 2024-02-06 트리시다, 인크. 경구 투여를 위한 양성자-결합 중합체
IL322207A (en) 2014-12-10 2025-09-01 Tricida Inc Proton-binding polymers for oral administration
ITUB20159278A1 (it) * 2015-12-23 2017-06-23 Rjw Pharma Llc Procedimento per la sintesi di patiromer
CN105622602A (zh) * 2016-01-30 2016-06-01 合肥华方医药科技有限公司 一种沙坦类小檗碱偶合物制备方法及其医药用途
IL262660B2 (en) 2016-05-06 2024-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
US12522682B2 (en) 2020-03-27 2026-01-13 Vifor (International) Ltd. Synthesis of methyl 2-fluoroacrylate
CN111978590B (zh) * 2020-09-04 2021-02-12 四川大学 一种沸石-肝素模拟聚合物共混微球、其制备方法及其应用
KR102647158B1 (ko) 2021-03-24 2024-03-15 강원대학교산학협력단 신규한 페디오코커스 악시딜락티시 균주 및 상기 균주를 이용하여 발효시킨 대두 발효물의 다양한 용도
US20240139234A1 (en) * 2021-11-17 2024-05-02 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Pharmaceutical polymer for treating hyperkalemia and preparation method thereof

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US487958A (en) * 1892-12-13 Patrick mccann
US2340111A (en) 1942-07-03 1944-01-25 Gen Electric Process for removing cations from liquid media
US2611730A (en) 1950-09-02 1952-09-23 Simth Kline & French Lab Medical preparation for reducing the body level of sodium
US2798053A (en) 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3499960A (en) 1965-01-25 1970-03-10 Merck & Co Inc Palatable coated particles of an anion exchange resin
FR2171934B1 (cg-RX-API-DMAC7.html) 1972-02-16 1974-09-13 Rhone Poulenc Sa
US3974272A (en) 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US4143130A (en) 1977-08-29 1979-03-06 Warren-Teed Laboratories, Inc. Method for treating kidney stones
US4470975A (en) 1977-10-21 1984-09-11 The Johns Hopkins University Method and composition for the elimination of water from an animal body
US4191812A (en) 1978-09-19 1980-03-04 Rohm And Haas Company Ion exchange process involving emulsion ion exchange resins
US4362711A (en) 1980-07-11 1982-12-07 Evreka Inc. Blood cholesterol level reducing agent and method
DE3149136A1 (de) 1981-12-11 1983-06-23 Robert Bosch Gmbh, 7000 Stuttgart Einrichtung zur regelung des kraftstoff-luftverhaeltnisses bei brennkraftmaschinen
JPS6090243A (ja) 1983-10-25 1985-05-21 Nitto Boseki Co Ltd 小球状モノアリルアミン橋かけ重合体の製造方法
US5238924A (en) 1984-05-03 1993-08-24 Merck & Co., Inc. Treatment of renal diseases with ace inhibitors
US4747881A (en) 1985-02-05 1988-05-31 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US5186937A (en) 1985-06-07 1993-02-16 A.E.C. Societe De Chimie Organique Et Biologique Composition for feeding ruminants
IT1190349B (it) 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
JPS63218713A (ja) 1987-02-17 1988-09-12 Daikin Ind Ltd α−フルオロアクリル酸系重合体ならびに用途
US4837015A (en) 1987-03-05 1989-06-06 Carolina Medical Products Company, Inc. Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels
US5210079A (en) 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists
FR2634377B1 (fr) 1988-06-30 1991-09-27 Cortial Nouvelle forme pharmaceutique a liberation prolongee a base d'un complexe resine-principe actif
GB8817015D0 (en) 1988-07-16 1988-08-17 Reckitt & Colmann Prod Ltd Method of treatment
US5236701A (en) 1989-07-19 1993-08-17 Lowchol Scientific Inc. Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol
DE3928990A1 (de) 1989-09-01 1991-03-07 Bayer Ag Verfahren zur herstellung von (alpha)-fluoroacrylsaeurederivaten
US5112993A (en) 1989-11-14 1992-05-12 E. I. Du Pont De Nemours And Company Process for the preparation of difluoromaleic anhydride
US5188825A (en) 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
US5091175A (en) 1990-05-14 1992-02-25 Erbamont Inc. Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane
DE69016014T2 (de) 1990-07-04 1995-08-31 Marcin Krotkiewski Blutdrucksenkendes Präparat.
IE914179A1 (en) 1990-12-07 1992-06-17 Ici Plc Nitrogen derivatives
US5162110A (en) 1990-12-19 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding theophylline to ion exchange resins
US5281631A (en) 1991-12-20 1994-01-25 Arch Development Corp. Phosphonic acid based ion exchange resins
DK0656029T3 (da) 1992-08-20 1999-02-15 Du Pont Tværbundne polymere ammoniumsalte
WO1994027619A1 (en) 1993-05-20 1994-12-08 Geltex Pharmaceuticals, Inc. Process for adjusting ion concentration in a patient and compositions therefor
US5487888A (en) 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5607669A (en) 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5618530A (en) 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
WO1995014531A1 (en) 1993-11-25 1995-06-01 Salternate B.V. Particles for binding monovalent cations, use of such particles as well as methods for scavenging and removing sodium and/or potassium ions
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5846990A (en) 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
JP3885130B2 (ja) 1996-06-11 2007-02-21 株式会社大塚製薬工場 グアニジノ化合物低下剤並びに水分及びカリウムイオン吸着剤
AU3649697A (en) 1996-06-27 1998-01-14 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US5935599A (en) 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
JPH10130154A (ja) 1996-10-29 1998-05-19 Otsuka Pharmaceut Factory Inc 腎疾患患者用延命率改善薬
KR100440544B1 (ko) 1998-07-31 2004-07-15 니켄 가가쿠 가부시키가이샤 양이온 교환수지 제제
US6294163B1 (en) 1998-10-02 2001-09-25 Geltex Pharmaceuticals, Inc. Polymers containing guanidinium groups as bile acid sequestrants
HUP0104249A3 (en) 1998-11-06 2002-06-28 G D Searle & Co Chicago Pharmaceutical composition for combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
CA2355829A1 (en) 1999-01-07 2000-07-13 Louise Templeton Multiparticulate oral dosage forms
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
US20020054903A1 (en) 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
US6569910B1 (en) 1999-10-27 2003-05-27 Basf Aktiengesellschaft Ion exchange resins and methods of making the same
US20030027789A1 (en) 2000-01-14 2003-02-06 Ippei Yamaoka Inhibitors against sodium ion absorption, and preventive or therapeutic agents and foods containing the same
FR2812632B1 (fr) 2000-08-07 2003-03-07 Solvay Procede pour la synthese de composes fluoroorganiques
US6908609B2 (en) 2000-11-20 2005-06-21 Dow Global Technologies Inc. In vivo use of water absorbent polymers
AU2002242103A1 (en) 2001-02-06 2002-08-19 Ash Medical Systems, Inc. Monovalent-selective cation exchangers as oral sorbent therapy
US7033639B2 (en) 2001-05-16 2006-04-25 Rohm And Haas Company Polyaniline coating composition
US6881484B2 (en) 2001-05-30 2005-04-19 Mitsubishi Kagaku Iatron, Inc. Core-shell particle including signal-generating substance enclosed therein and process for producing the same
AR036710A1 (es) 2001-10-01 2004-09-29 Basf Ag Proceso para preparar compuestos de alquilarilo y sulfonatos de los mismos
JP2004149525A (ja) 2002-10-09 2004-05-27 Sekisui Chem Co Ltd カリウムイオン吸着剤及びその製造方法、並びに高カリウム血症治療剤
CA2516457C (en) 2003-02-25 2011-12-06 Finnfeeds Finland Oy A simulated moving bed system and process
CA2551528A1 (en) 2003-12-31 2005-07-21 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
US7854924B2 (en) 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
KR101153035B1 (ko) 2004-03-30 2012-06-11 리립사, 인크. 이온 결합 조성물
US8282960B2 (en) 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
US7429394B2 (en) 2004-03-30 2008-09-30 Relypsa, Inc. Ion binding compositions
US8192758B2 (en) 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US7556799B2 (en) 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
JP2009510126A (ja) * 2005-09-30 2009-03-12 レリプサ, インコーポレイテッド 哺乳類の胃腸管からカリウムイオンを選択的に除去するための方法および組成物
WO2007038801A2 (en) 2005-09-30 2007-04-05 Ilypsa, Inc. Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof
CN101321519A (zh) 2005-09-30 2008-12-10 伊立普萨公司 制备含有交联壳的核-壳型复合物的方法及其得到的核-壳型复合物
US20070092553A1 (en) 2005-10-21 2007-04-26 Pfab Lp Compositions and methods of making rapidly dissolving lonically masked formulations
US20070248564A1 (en) 2006-04-25 2007-10-25 Roxane Laboratories, Inc. Formulation of sodium polystyrene sulfonate suspension for the treatment of hyperkalemia
JP2010538016A (ja) 2007-08-29 2010-12-09 ソーベント セラピューティクス インコーポレイテッド 異なる対イオン含有量を有する吸収性ポリマー組成物、ならびにその調製および使用の方法
WO2010022380A2 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
EP4201408B1 (en) * 2008-08-22 2025-06-25 Vifor (International) Ltd. Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
US20100111892A1 (en) 2008-08-22 2010-05-06 Relypsa, Inc. Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
WO2010022381A1 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
WO2010132662A1 (en) * 2009-05-13 2010-11-18 Relypsa, Inc. Powder formulations of potassium-binding active agents
TR201807469T4 (tr) 2010-03-20 2018-06-21 Relypsa Inc Polifloroakrilat partikülleri hazırlamaya yönelik kesintisiz işlem.
US10557856B2 (en) * 2010-09-24 2020-02-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Biomarkers of renal injury
US8697132B2 (en) * 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
AU2012205680A1 (en) 2011-01-10 2013-08-22 Sorbent Therapeutics, Inc. Compositions comprising crosslinked cation- binding polymers and a base, uses thereof
CA2827056C (en) 2011-02-11 2020-07-14 Zs Pharma, Inc Microporous zirconium silicate for the treatment of hyperkalemia
CN110028603A (zh) 2011-06-27 2019-07-19 瑞立普萨公司 用于将聚合酯转化为聚合酸的方法
CN108276277A (zh) 2011-06-27 2018-07-13 瑞立普萨公司 丙烯酸酯及衍生物的氟化
IN2015DN01369A (cg-RX-API-DMAC7.html) * 2012-07-19 2015-07-03 Relypsa Inc
ES3059226T3 (en) 2012-10-08 2026-03-19 Vifor Int Ltd Potassium-binding agents for treating hypertension and hyperkalemia

Similar Documents

Publication Publication Date Title
Karkar et al. Prescription of CRRT: a pathway to optimize therapy
ES2726710T3 (es) Dispositivo para el tratamiento extracorpóreo de la sangre
US8864699B2 (en) High citrate dialysate and uses thereof
JP2022106914A5 (cg-RX-API-DMAC7.html)
Yessayan et al. Continuous renal replacement therapy for the management of acid-base and electrolyte imbalances in acute kidney injury
JP2019514965A5 (cg-RX-API-DMAC7.html)
Sakarcan et al. Hyperphosphatemia in tumor lysis syndrome: the role of hemodialysis and continuous veno-venous hemofiltration
JP2009516575A (ja) 体外血液処理のためのクエン酸塩抗凝固システム
IL273960B2 (en) Nonabsorable compositions for use in treating or preventing metabolic acidosis
CN1230118A (zh) 高磷血症治疗剂
JP2012533582A5 (cg-RX-API-DMAC7.html)
JP2024038034A5 (cg-RX-API-DMAC7.html)
HRP20231469T1 (hr) Poboljšani protokol za liječenje lupus nefritisa
Nakamura et al. Acute encephalopathy due to aluminum toxicity successfully treated by combined intravenous deferoxamine and hemodialysis
JP2009508822A5 (cg-RX-API-DMAC7.html)
Yamashita et al. Clinical effect of pre-dilution hemodiafiltration based on the permeation of the hemodiafilter
JP2016503768A (ja) 透析組成物
Saraceno et al. Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases
Lorenzin et al. Solute and water kinetics in continuous therapies
Kindgen-Milles et al. Treatment of metabolic alkalosis during continuous renal replacement therapy with regional citrate anticoagulation
Messa et al. Calcium and phosphate control by dialysis treatments
Marshall Current status of dosing and quantification of acute renal replacement therapy. Part 1: Mechanisms and consequences of therapy under‐delivery
CN103638526B (zh) 一种血液净化用制剂及其制备方法与应用
BERNIEH et al. SAT-229 FIFTEEN YEAR EXPERICE OF USING LOW MOLECULAR WEIGHT HEPARIN “ENOXAPARIN” IN HEMODIALYSIS PATIENTS
JP6337175B2 (ja) 急性又は慢性腎不全患者の血液からタンパク質結合毒素を除去するための透析法に使用される医薬組成物。